Q2 FY26 results: Net profit down 24% YoY at Rs 20 cr

EBITDA margin compressionResults View source PDF Explain this filing

LINCOLN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.3%Reaction day

₹530.00

prior close

₹516.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-4.2% vs market

Pharmaceuticals peers, median of 157sector-0.0%-4.2% vs sector

On the reaction day the stock moved 4.2 pts less than Nifty Microcap 250 and 4.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.1

10m

+0.8

15m

+0.1

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.3-0.1-4.2-0.0-4.2

Next day

-0.2-0.2-0.0-0.5+0.3

+1.3+0.4+0.9-0.4+1.7

+0.7-0.4+1.1-1.1+1.8

+1.1-0.6+1.6-1.4+2.4

+0.8-0.9+1.7-1.6+2.4

-2.5-3.0+0.5-3.3+0.9

15d

-6.6-3.9-2.7-3.4-3.2

-7.8-4.8-3.0-4.0-3.8

-8.3-7.8-0.5-6.6-1.7

+20.6-7.2+27.8-8.8+29.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lincoln Pharma reported Q2 FY26 net profit of Rs 20.01 crore, down 24.06% YoY. Total income was Rs 170.60 crore, down 0.34%. EBITDA fell 14.86% to Rs 32.66 crore. EPS at Rs 9.98. H1 FY26 net profit declined 4.64% to Rs 47.71 crore on total income of Rs 339.93 crore (up 3.36%). Company targets Rs 1,000 crore revenue in 3 years. Dividend of Rs 1.80 per share approved.

Likely market impact

Margin pressure evident with profit down 24% on flat revenue. Targets of Rs 1,000 crore revenue and debt-free status provide support.